Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPeralta-Garcia, Alejandro
dc.contributor.authorTorrens-Fontanals, Mariona
dc.contributor.authorStepniewski, Tomasz Maciej
dc.contributor.authorGrau Exposito, Judit
dc.contributor.authorPerea Pérez, David
dc.contributor.authorAyinampudi, Vikram
dc.contributor.authorBuzón Gómez, María José
dc.contributor.authorGenesca Ferrer, Meritxell
dc.date.accessioned2022-06-15T11:45:19Z
dc.date.available2022-06-15T11:45:19Z
dc.date.issued2021-12
dc.identifier.citationPeralta-Garcia A, Torrens-Fontanals M, Stepniewski TM, Grau-Expósito J, Perea D, Ayinampudi V, et al. Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells. Int J Mol Sci. 2021 Dec;22(24):13592.
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/11351/7684
dc.descriptionCOVID-19; Drug repurposing; Viral cell entry assays
dc.description.abstractSince the start of the COVID-19 outbreak, pharmaceutical companies and research groups have focused on the development of vaccines and antiviral drugs against SARS-CoV-2. Here, we apply a drug repurposing strategy to identify drug candidates that are able to block the entrance of the virus into human cells. By combining virtual screening with in vitro pseudovirus assays and antiviral assays in Human Lung Tissue (HLT) cells, we identify entrectinib as a potential antiviral drug.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesInternational Journal of Molecular Sciences;22(24)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMedicaments antivírics
dc.subjectCOVID-19 (Malaltia)
dc.subjectMedicaments - Ús
dc.subject.meshAntiviral Agents
dc.subject.mesh/pharmacology
dc.subject.meshDrug Repositioning
dc.subject.meshCoronavirus Infections
dc.titleEntrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/ijms222413592
dc.subject.decsantivíricos
dc.subject.decs/farmacología
dc.subject.decsnuevas indicaciones de medicamentos
dc.subject.decsinfecciones por Coronavirus
dc.relation.publishversionhttps://doi.org/10.3390/ijms222413592
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Peralta-Garcia A, Torrens-Fontanals M] Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University (UPF), 08003 Barcelona, Spain. [Stepniewski TM] Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University (UPF), 08003 Barcelona, Spain. InterAx Biotech AG, PARK InnovAARE, 5234 Villigen, Switzerland. [Grau-Expósito J, Perea D, Buzón MJ, Genescà M] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Ayinampudi V] InterAx Biotech AG, PARK InnovAARE, 5234 Villigen, Switzerland
dc.identifier.pmid34948390
dc.identifier.wos000737887800001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record